表皮生长因子受体-酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的疗效分析  

Efficacy analysis of epidermal growth factor receptor-tyrosine kinase inhibitor combined with chemotherapy in advanced non-small cell lung cancer

作　　者：王鹏[1] 董玉[1] 丁海霞[1] 董卫侠 王冠杰[1] WANG Peng;DONG Yu;DING Haixia;DONG Weixia;WANG Guanjie(Departmentof Respiratory and Critical Care Medicine,Xi’an Central Hospital,Xi’an 710001,Shaanxi,China)

机构地区：[1]西安市中心医院呼吸与危重症医学科,西安7100010

出　　处：《癌症进展》2020年第24期2539-2542,共4页Oncology Progress

摘　　要：目的探讨表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法根据治疗方法的不同将150例经基因测序均为EGFR突变阳性的Ⅲb或Ⅳ期NSCLC患者分为观察组和对照组,每组75例。对照组接受EGFR-TKI治疗,观察组在对照组的基础上联合化疗药物进行治疗。比较两组患者的临床疗效、无进展生存期(PFS)和不良反应发生情况。结果观察组患者的客观有效率(ORR)和疾病控制率(DCR)均高于对照组患者(P﹤0.05)。观察组患者的中位PFS为13.5个月(95%CI:11.621~15.349),长于对照组患者的9个月(95%CI:7.903~10.889)(P﹤0.05)。两组患者的不良反应发生情况比较,差异无统计学意义(P﹥0.05)。两组患者均未发生4级严重不良反应,且观察组并未出现3级皮疹和骨髓抑制的不良反应。结论EGFR-TKI联合化疗治疗晚期NSCLC患者临床疗效显著,可延长患者的PFS,且未增加不良反应。Objective To investigate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor,(EGFR-TKI)combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Method 150 stage Ⅲb or Ⅳ NSCLC patients with positive EGFR mutationby gene sequencing were divided into observation group(n=75,treated with EGFR-TKI+chemotherapy)and control group(n=75,treated with EGFR-TKI).The clinical efficacy,progression-free survival(PFS)and adverse reactions were compared between the two groups.Result The objective effective rate(ORR)and disease control rate(DCR)in the observation group were significantly higher than those in the control group(P<0.05).The median PFS of the observation group and the control group was 13.5 months(95%CI:11.621-15.349)and 9 months(95%CI:7.903-10.889),respectively(P<0.05).There were no significant differences for adverse reactions between the two groups(P>0.05).There were no grade 4 adverse reactions in both groups,and there were no grade 3 rashes and myelosuppression in the observation group.Conclusion EGFR-TKI combined with chemotherapy is effective in the treatment of patients with advanced NSCLC,which can effectively prolong PFS and reduce the adverse reactions.

关 键 词：表皮生长因子受体-酪氨酸激酶抑制剂 化疗 非小细胞肺癌 无进展生存期 安全性 

分 类 号：R734.2[医药卫生—肿瘤]